Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
10
NAK, A Potential Therapeutic Target for Aids
Award last edited on: 3/4/02
Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$112,854
Award Phase
1
Solicitation Topic Code
-----
Principal Investigator
Arie Abo
Company Information
Onyx Pharmaceuticals Inc
249 East Grand Avenue
South San Francisco, CA 94080
(650) 266-0000
ir@onyx-pharm.com
www.onyx-pharm.com
Location:
Single
Congr. District:
14
County:
San Mateo
Phase I
Contract Number:
1R43AI045262-01A1
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2000
Phase I Amount
$112,854
The accessory protein HIV-Nef plays an important role in the regulation of HIV pathogenesis. Recently we and others have shown that Nef is associated with the host protein kinase known as Nef Associated kinase (NAK). Recruitment of NAK by Nef is an important step for HIV production. NAK inhibitors will introduce a novel class of anti-HIV drugs that will target the host protein rather than viral proteins. To identify NAK, we will purify NAK from T Jurkat cells stably expressing Nef and will use the sequence information to obtain the full length DNA. Our preliminary results suggest that NAK is co-purified with Pak1 and Nef interacts with Pak1 in-vitro and in-vivo. We will further characterize the Pak1 and Nef interaction and will establish if NAK is identical to Pak1. We will make recombinant NAK to study the biochemical events leading to NAK activation and will test the effect of NAK mutants on HIV production. This approach may lead us to the discovery of anti-HIV drugs that will maintain efficacy in a virus that exhibits a high frequency of mutations. PROPOSED COMMERCIAL APPLICATIONS: We previously have shown that the association of HIV Nef with the host protein NAK is essential for HIV replication. Our preliminary results indicate that NAK is identical to known kinase Pak1. The development of a NAK specific inhibitor will allow us to identify a novel class of anti-HIV agents. Our research and development will introduce a novel approach in the development of anti viral agents and will expand our understanding of the mechanism of HIV pathogenesis
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.